TRVN - TREVENA INC
Previous close
2.465
-2.560 -103.854%
Share volume: 0
Last Updated: Mon 07 Oct 2024 08:25:42 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$5.02
0.00
0.00%
Fundamental analysis
6%
Profitability
2%
Dept financing
8%
Liquidity
50%
Performance
0%
Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-62.47%
6 Months
534.78%
1 Year
107.06%
2 Year
11.45%
Key data
Stock price
$2.46
DAY RANGE
$2.42 - $5.02
52 WEEK RANGE
$0.20 - $7.85
52 WEEK CHANGE
$105.95
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Carrie L. Bourdow
Region: US
Website: trevena.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: trevena.com
Employees: 40
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Trevena focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain.
Recent news